Did you know that therapies once thought to be science fiction, like CAR T-cell treatment and regenerative stem cell therapies, are now becoming a reality in Malaysia? It is worthy to note that Malaysia’s life sciences industry is rapidly adopting advanced, personalized treatments that target the root causes of disease, from genetic disorders to cancer.
Moreover, precision medicine, biological therapies, and data-driven innovation are no longer just global trends; they are shaping Malaysia’s healthcare landscape.
Yet, the journey is far from simple. The path to modernization in life sciences is paved with challenges, both structural and scientific. Furthermore, regulatory hurdles remain one of the biggest obstacles.
Additionally, lengthy and complex approval processes often delay the entry of breakthrough treatments, pushing patients to seek care in neighboring countries with more adaptive systems. Patient acceptance presents another barrier.
Advanced therapies like cell and gene treatments are still new to the public, and their science can be difficult to grasp. Furthermore, education and awareness are crucial for building trust and understanding that these therapies have the potential to cure, not just manage, diseases.
Finally, there is the challenge of cost. Precision medicine, by its very nature, is individualized and therefore expensive to research and produce. Developing these treatments demands significant investment and sophisticated infrastructure. For most patients, affordability remains the biggest concern.
Amid these challenges, Ascendnex has emerged as a pioneering force bridging science, technology, and accessibility by combining cutting-edge biological research with a commitment to making life-changing therapies affordable and available to more people.
With its first-mover advantage, global collaborations, and unwavering focus on innovation, the company is helping shape Malaysia’s future in healthcare. This future will be not only more advanced, but also more compassionate and inclusive.
From Vision to Reality
In 2018, Ascendnex began its journey not as a manufacturer or a distributor, but as a consulting firm with a singular mission: to navigate the complexities of the life sciences sector and bring advanced medical solutions to Malaysia and beyond.
From the very beginning, the company set its sights on emerging technologies like stem cells, CAR T-cells for leukemia, and stem cell therapies for arthritis and diabetes, aiming to introduce treatments that could truly transform lives.
In those early years, Ascendnex quickly earned recognition for its expertise. It became a trusted guide for clients, helping them traverse regulatory pathways, understand market dynamics, and overcome scientific challenges.
Through this work, the company built a strong network and gained deep insight into the pressing needs of healthcare and biotech industries.
Guided by its core philosophy, “Grow More”, the company is committed to mutual growth with its clients. Its strategy was simple yet ambitious: build bridges to new markets and expand intelligently.
As time passed, Ascendnex’s role began to evolve. From a consultancy, it transformed into a full-fledged commercial partner, leveraging its knowledge and connections to bridge the gap between innovative life science products and healthcare providers. Furthermore, the company began introducing cutting-edge medical technologies to underserved regions, including Sri Lanka and the Philippines, extending its impact far beyond Malaysia.
The next chapter in Ascendnex’s story was perhaps the boldest. “Recognizing gaps in the market, we decided to create rather than advise and distribute. This vision gave birth to our two specialized subsidiaries: Elixir and Celler Therapeutics,” states Karthik Chandran, Founder at Ascendnex.
Elixir was designed to elevate patient care through precision-engineered medical devices, with products reaching international markets such as Dubai, Phillipines and UK. Meanwhile, Celler Therapeutics marked Ascendnex’s foray into advanced therapies, focusing on cell and gene treatments capable of curing genetic diseases, combating cancer, and changing lives.
Today, Ascendnex stands has devised a synergistic ecosystem, seamlessly uniting consulting, commercial, and manufacturing capabilities. Insights from its consulting and sales teams continuously refine its manufacturing operations, ensuring every product from Elixir and Celler is both scientifically robust and market-ready.
In less than a decade, Ascendnex has forayed from a modest consultancy to a global innovator shaping the future of medicine. As it approaches its 10th anniversary, the company continues to embrace its vision: growth, innovation, and an unwavering commitment to making a meaningful impact on healthcare worldwide.
Advancing Regenerative Therapies
Ascendnex offers a diverse suite of products and services across two main focus areas —orthopedics and oncology.
In the orthopedic segment, Ascendnex specializes in stem cell therapy for osteoarthritis, one of its most in-demand treatments in Malaysia. Additionally, the company also provides a range of medical devices, including hyaluronic acid injectables and orthopedic implants to support joint care and mobility restoration.
In the oncology segment, Ascendnex focuses on CAR T-cell therapy for cancer patients designed to target and eliminate malignant cells with high precision. Alongside this, Ascendnex is also conducting research in neurodegenerative diseases, expanding its efforts into new frontiers of medical science.
In total, Ascendnex’s flagship offerings, stem cell therapy for osteoarthritis and CAR T-cell therapy for cancer underscore Malaysia’s growing embrace of regenerative and personalized care.
Data-Driven Medicine
Technology and innovation forms the backbone of Ascendnex growth strategy. The company integrates artificial intelligence (AI) and genomics to predict treatment outcomes in cases of remission, relapse, or survival duration for patients receiving advanced therapies.
Its experts in genetic mapping use predictive algorithms to forecast disease progression and treatment response. This helps identify potential side effects in advance, enabling safer and more personalized treatment plans.
By blending biological science, AI, and genetics, Ascendnex is building a more intelligent and adaptive healthcare model, ensuring that every patient benefits from data-driven insights and the most advanced precision therapies available.
We envision becoming a global leader by challenging the rising cost of healthcare by reducing production expenses and ensuring affordable access to advanced treatments
Backbone of Excellence
Ascendnex draws its consulting strength from a highly multidisciplinary core team led by its founder. The team includes a strong network of medical professionals, scientists, and business experts, creating a well-rounded foundation for both scientific and strategic consulting.
The consulting division is spearheaded by the Founder, Dr Karthik Chandran, supported by qualified doctors including oncologists, orthopedic surgeons, and hematologists. The doctors bring deep clinical insight into cancer treatment, regenerative medicine, and orthopedic care. Alongside them, the team includes statisticians, clinical research officers (CROs), and entrepreneurs with proven experience in company management and operations.
On the laboratory and medical device side, Ascendnex employs a team of eight to nine PhD holders with advanced expertise in research and product development. Additionally, the company also maintains international collaborations with institutions and experts from China, Russia, Turkey, the United States, and the United Kingdom, providing technical support and access to specialized equipment.
Together, this global and multidisciplinary team delivers holistic consulting solutions that combine scientific excellence, regulatory understanding, and business intelligence which strengthens Ascendnex ’s position as a trusted partner in the life sciences industry.
The Path for the Future
Having already evolved from consultancy to medical device and cell and gene therapy manufacturing, Ascendnex now aims to strengthen its presence across multiple facets of modern medicine.
Looking forward, Ascendnex aims to build a sustainable, patient-centric ecosystem that combines technological advancement with social responsibility, by growing not just in scale, but in purpose, impact and contribution to global health. Karthik concludes by stating “We envision becoming a global leader by challenging the rising cost of healthcare by reducing production expenses and ensuring affordable access to advanced treatments”.
We use cookies to ensure you get the best experience on our website. Read more...
.jpg "Technology in Cancer Care: A story of evolving paradigms")
.jpg "Bringing Shop Floor to Manufacturer's palm: Smart Factory Solutions for tomorrow")
